502 related articles for article (PubMed ID: 33273963)
1. Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.
Lin J; Lin Y; Huang Z; Li X
Comput Math Methods Med; 2020; 2020():8836493. PubMed ID: 33273963
[TBL] [Abstract][Full Text] [Related]
2. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
3. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
[TBL] [Abstract][Full Text] [Related]
4. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.
Ma W; Li W; Xu L; Liu L; Xia Y; Yang L; Da M
Pathol Oncol Res; 2021; 27():1609852. PubMed ID: 34566519
[No Abstract] [Full Text] [Related]
5. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.
Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J
Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203
[No Abstract] [Full Text] [Related]
6. Gene expression and immune infiltration in melanoma patients with different mutation burden.
Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
[TBL] [Abstract][Full Text] [Related]
7. Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma.
Kang K; Xie F; Mao J; Bai Y; Wang X
Front Oncol; 2020; 10():573141. PubMed ID: 33072607
[No Abstract] [Full Text] [Related]
8. Identifying
Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
PeerJ; 2023; 11():e16618. PubMed ID: 38099311
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
10. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
11. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
Zhang C; Li Z; Qi F; Hu X; Luo J
Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
[TBL] [Abstract][Full Text] [Related]
12. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
13. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
[TBL] [Abstract][Full Text] [Related]
14. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
[TBL] [Abstract][Full Text] [Related]
15. Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.
Xie Z; Li X; Lun Y; He Y; Wu S; Wang S; Sun J; He Y; Xin S; Zhang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107090. PubMed ID: 33091816
[TBL] [Abstract][Full Text] [Related]
16. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
Luo C; Chen J; Chen L
Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
[TBL] [Abstract][Full Text] [Related]
17. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
[TBL] [Abstract][Full Text] [Related]
18. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
19. The Identification and Validation of a Robust Immune-Associated Gene Signature in Cutaneous Melanoma.
Song LB; Luan JC; Zhang QJ; Chen L; Wang HY; Cao XC; Song NH; Lu Y
J Immunol Res; 2021; 2021():6686284. PubMed ID: 33688507
[TBL] [Abstract][Full Text] [Related]
20. Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer.
Wu Z; Wang M; Liu Q; Liu Y; Zhu K; Chen L; Guo H; Li Y; Shi B
Int J Med Sci; 2020; 17(1):89-96. PubMed ID: 31929742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
